These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22728753)

  • 1. Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.
    De Luca A; de Gaetano Donati K; Cozzi-Lepri A; Colafigli M; De Curtis A; Capobianchi MR; Antinori A; Giacometti A; Magnani G; Vullo V; Cauda R; Iacoviello L; d'Arminio Monforte A;
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):e98-101. PubMed ID: 22728753
    [No Abstract]   [Full Text] [Related]  

  • 2. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.
    Padilla S; Masiá M; García N; Jarrin I; Tormo C; Gutiérrez F
    BMC Infect Dis; 2011 Feb; 11():40. PubMed ID: 21294867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy.
    Kristoffersen US; Kofoed K; Kronborg G; Benfield T; Kjaer A; Lebech AM
    HIV Med; 2009 Nov; 10(10):627-33. PubMed ID: 19891054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.
    Palella FJ; Gange SJ; Benning L; Jacobson L; Kaplan RC; Landay AL; Tracy RP; Elion R
    AIDS; 2010 Jul; 24(11):1657-65. PubMed ID: 20588104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
    Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
    AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
    Patel P; Bush T; Overton T; Baker J; Hammer J; Kojic E; Conley L; Henry K; Brooks JT;
    Antivir Ther; 2012; 17(4):755-61. PubMed ID: 22301072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
    Calza L; Magistrelli E; Danese I; Colangeli V; Borderi M; Bon I; Re MC; Mancini R; Conti M; Motta R; Viale P
    Curr HIV Res; 2016; 14(1):61-70. PubMed ID: 26531764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject.
    Rossotti R; Maggioni M; Merli M; Orcese C; Iavarone M; Puoti M
    AIDS; 2018 Jul; 32(12):1727-1729. PubMed ID: 30001246
    [No Abstract]   [Full Text] [Related]  

  • 9. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.
    Schafer JJ; Short WR; Squires KE
    Pharmacotherapy; 2010 Oct; 30(10):1072-83. PubMed ID: 20874044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abacavir and increased risk of myocardial infarction.
    Post FA; Campbell LJ
    Lancet; 2008 Sep; 372(9641):803; author reply 804-5. PubMed ID: 18774412
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.
    ;
    AIDS; 2008 Sep; 22(14):F17-24. PubMed ID: 18753925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the combination of efavirenz and abacavir in HIV-infected patients failing antiretroviral therapy.
    Tenorio AR; Irlanda IE; Narkiewicz E; Smith KY; Kessler HA; Sha BE
    AIDS; 2000 Jul; 14(10):1470-1. PubMed ID: 10930173
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.
    Dorjee K; Choden T; Baxi SM; Steinmaus C; Reingold AL
    Int J Antimicrob Agents; 2018 Nov; 52(5):541-553. PubMed ID: 30040992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension Risk with Abacavir Use among HIV-Infected Individuals: A Nationwide Cohort Study.
    Kim J; Bang JH; Shin JY; Yang BR; Lee J; Park BJ
    Yonsei Med J; 2018 Dec; 59(10):1245-1252. PubMed ID: 30450860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals.
    Marcus JL; Neugebauer RS; Leyden WA; Chao CR; Xu L; Quesenberry CP; Klein DB; Towner WJ; Horberg MA; Silverberg MJ
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):413-9. PubMed ID: 26536316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV disease is associated with increased biomarkers of endothelial dysfunction despite viral suppression on long-term antiretroviral therapy in Botswana.
    Mosepele M; Mohammed T; Mupfumi L; Moyo S; Bennett K; Lockman S; Hemphill LC; Triant VA
    Cardiovasc J Afr; 2018 May/Jun 23; 29(3):155-161. PubMed ID: 29771268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
    Kim C; Gupta SK; Green L; Taylor BM; Deuter-Reinhard M; Desta Z; Clauss M
    Antivir Ther; 2011; 16(8):1335-9. PubMed ID: 22155915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team.
    Kline MW; Blanchard S; Fletcher CV; Shenep JL; McKinney RE; Brundage RC; Culnane M; Van Dyke RB; Dankner WM; Kovacs A; McDowell JA; Hetherington S
    Pediatrics; 1999 Apr; 103(4):e47. PubMed ID: 10103339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
    McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
    Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sweet's syndrome following abacavir therapy.
    Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
    J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.